Leading clinician and researcher in Pulmonary Disease TherapeuticsNEW HAVEN, Conn., Feb. 19, 2025 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company ...

Additional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices ...

Globe Life earned 2.5 stars out of 5 for overall performance. Founded in 1951, Globe Life offers a mix of term and permanent life insurance. The company highlights its initial low cost ...

MANP was originally discovered by John C. Burnett Jr., MD, Director of the Cardiorenal Research Laboratory at Mayo Clinic. E-Star and Mayo Clinic entered into a worldwide exclusive license agreement ...

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE ... for the treatment of Resistant Hypertension (BOLD-HTN). MANP was originally discovered by John C. Burnett Jr., MD, Director of the Cardiorenal ...

and ocular hypertension (OHT). The Phase II trials (Osprey and Apteryx) successfully met all primary and secondary endpoints. Qlaris Bio will present a corporate update at the Glaucoma 360 New ...

The paper focuses on how limited access to healthier foods in these areas contributes to a higher prevalence of chronic diseases such as hypertension and obesity, compared to wealthier neighborhoods.